Mathangi Gopalakrishnan

List of Publications by Year
in descending order

40 papers	456 citations	840776 11 h-index	794594 19 g-index
42 all docs	42 docs citations	42 times ranked	597 citing authors

#	Article	IF	Citations
1	Pharmacokinetic Studies of Florfenicol in Koi Carp and Threespot GouramiTrichogaster trichopterusafter Oral and Intramuscular Treatment. Journal of Aquatic Animal Health, 2005, 17, 129-137.	1.4	68
2	Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation. Pharmaceutical Statistics, 2017, 16, 232-249.	1.3	58
3	Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system. Contraception, 2016, 94, 353-356.	1.5	29
4	The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues. Journal of Clinical Psychiatry, 2020, 81, .	2.2	20
5	Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	19
6	Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials. Clinical Pharmacokinetics, 2021, 60, 527-540.	3.5	19
7	Exposure–response analysis after subcutaneous administration of RBP–7000, a once–a–month long–acting Atrigel formulation of risperidone. British Journal of Clinical Pharmacology, 2017, 83, 1476-1498.	2.4	18
8	Parent–Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT–888), a PARP Inhibitor, in Patients With <i>BRCA 1/2</i>–Mutated Cancer or PARP–Sensitive Tumor Types. Journal of Clinical Pharmacology, 2017, 57, 977-987.	2.0	17
9	Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. Clinical Drug Investigation, 2017, 37, 937-946.	2.2	16
10	Racial association and pharmacotherapy in neonatal opioid withdrawal syndrome. Journal of Perinatology, 2019, 39, 1370-1376.	2.0	16
11	A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	16
12	Lacosamide Pharmacokinetics in a Critically Ill Patient Receiving Continuous Venovenous Hemofiltration. Pharmacotherapy, 2018, 38, e17-e21.	2.6	12
13	Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study. Acta Diabetologica, 2018, 55, 461-468.	2.5	11
14	Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications. JAMA Psychiatry, 2020, 77, 1064.	11.0	11
15	Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemotherapy and Pharmacology, 2019, 83, 319-328.	2.3	9
16	Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock. Pharmacotherapy, 2020, 40, 211-220.	2.6	9
17	Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics. Clinical Pharmacology and Therapeutics, 2021, 110, 589-594.	4.7	9
18	A Practice–Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE–01). Clinical and Translational Science, 2020, 13, 950-959.	3.1	8

#	ARTICLE	IF	CITATIONS
19	Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy, 2021, 41, 205-211.	2.6	8
20	Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. British Journal of Clinical Pharmacology, 2017, 83, 1688-1700.	2.4	7
21	Bayesian Forecasting Tool to Predict the Need for Antidote in Acute Acetaminophen Overdose. Pharmacotherapy, 2017, 37, 916-926.	2.6	7
22	A New Zealand White rabbit model of thrombocytopenia and coagulopathy following total body irradiation across the dose range to induce the hematopoietic-subsyndrome of acute radiation syndrome. International Journal of Radiation Biology, 2021, 97, S19-S31.	1.8	7
23	Interspecies Comparison and Radiation Effect on Pharmacokinetics of BIO 300, a Nanosuspension of Genistein, after Different Routes of Administration in Mice and Non-Human Primates. Radiation Research, 2022, 197, .	1.5	7
24	Development and validation of a HPLC–UV assay for quantification of levetiracetam concentrations in critically ill patients undergoing continuous renal replacement therapy. Biomedical Chromatography, 2018, 32, e4257.	1.7	6
25	A Quantitative Justification of Similarity in Placebo Response Between Adults and Adolescents With Acute Exacerbation of Schizophrenia in Clinical Trials. Clinical Pharmacology and Therapeutics, 2019, 106, 1046-1055.	4.7	6
26	Manufacturing biological medicines on demand: Safety and efficacy of granulocyte colony–stimulating factor in a mouse model of total body irradiation. Biotechnology Progress, 2020, 36, e2970.	2.6	6
27	Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. Journal of Clinical Pharmacology, 2017, 57, 247-254.	2.0	5
28	An Innovative Disease–Drug–Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate. Clinical and Translational Science, 2020, 13, 88-97.	3.1	5
29	Assessment of Similarity in Antipsychotic Exposure–Response Relationships in Clinical Trials Between Adults and Adolescents With Acute Exacerbation of Schizophrenia. Journal of Clinical Pharmacology, 2020, 60, 848-859.	2.0	5
30	A novel approach for personalized response model: deep learning with individual dropout feature ranking. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 165-179.	1.8	5
31	Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies. Clinical Cancer Research, 2017, 23, 6421-6429.	7.0	4
32	Model–Based Approach to Improve Clinical Outcomes in Neonates With Opioid Withdrawal Syndrome Using Real–World Data. Clinical Pharmacology and Therapeutics, 2021, 109, 243-252.	4.7	3
33	Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real–World Data: A Pharmacokinetic–Pharmacodynamic Modeling Approach. Journal of Clinical Pharmacology, 2022, 62, 733-746.	2.0	3
34	Evaluation of Switch–to–Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real–World Retrospective Cohort Study. Clinical Pharmacology and Therapeutics, 2021, 110, 443-451.	4.7	2
35	A prospective, real–world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADRE–02). British Journal of Clinical Pharmacology, 2021, 87, 4375-4385.	2.4	2
36	Response to racial association and pharmacotherapy in neonatal opioid withdrawal syndrome: thinking beyond genetics. Journal of Perinatology, 2020, 40, 691-692.	2.0	1

#	Article	IF	Citations
37	Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration. Psychiatric Research and Clinical Practice, 2021, 3, 38-45.	2.4	1
38	Development and Use of an Ex-Vivo In-Vivo Correlation to Predict Antiepileptic Drug Clearance in Patients Undergoing Continuous Renal Replacement Therapy. Pharmaceutical Research, 2022, , .	3.5	1
39	450. Evaluation of Linezolid Pharmacokinetics in Obese Patients with Severe Skin and Soft-Tissue Infections. Open Forum Infectious Diseases, 2019, 6, S221-S221.	0.9	0
40	Evaluation of an ex-vivo neonatal extracorporeal membrane oxygenation circuit on antiepileptic drug sequestration. Perfusion (United Kingdom), 2021, , 026765912110281.	1.0	0